With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.391604-55-0,2-(2,4-Difluorophenyl)pyridine,as a common compound, the synthetic route is as follows.,391604-55-0
2-bromopyridine (4.17g, 26.39mmol), 2,4- difluorophenyl boronic acid (5.00g, 31.66mmol), phosphorus tetrakistriphenylphosphine palladium (0.91g, 0.79mmol) and sodium carbonate (6.36g, 60.00mmol ) was dissolved in 100mL of tetrahydrofuran, 65 for 24 hours, cooling, water and dichloromethane, the organic layer was concentrated by column chromatography to obtain primary ligand (3.84g, yield 76.18%). The primary ligand (2.50g, 13.08mmol) and iridium chloride (2.30g, 6.23mmol) was dissolved in 15mL ethoxyethanol, the reaction mixture was 130 C 12h, then was added pyridine phosphate (2.72g, 12.46mmol) and sodium carbonate (3.30g, 31.15mmol), continue 130 reaction 24h. System cooling, water and dichloromethane, the organic layer was concentrated by column chromatography to obtain a yellow solid Ir1-001 (1.06g, yield: 21.5%).
The synthetic route of 391604-55-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; AAC Acoustic Technology Holdings Inc.; Pan, Yi; Zheng, Youxuan; Wu, Zhengguang; Wang, Yi; Zhou, Jie; Cao, Chenhui; (7 pag.)CN105837629; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI